NCT05276830Phase 2Terminated

An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2022-04-01Actual

Enrollment · participants5Actual

Source updated2026-08-11Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Agitation; Dementia

Treatments or interventions studied

BXCL501DrugAlso known as Dexmedetomidine
BXCL501DrugAlso known as Dexmedetomidine
Placebo filmDrugAlso known as Placebo

Primary outcomes · main study measures

Read the study measures

measure: Change in Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score; description: The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe).; timeFrame: 120 minutes

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history